logo-loader
viewArecor

Arecor signs R&D agreement with diabetes research charity JDRF

Arecor and JDRF will invest equal funds to develop AT271, a liquid combination of pramlintide and insulin

Arecor - Arecor signs agreement with diabetes research charity JDRF
The combined injection of these two drugs at mealtimes helps patients with type 1 diabetes manage the condition

Arecor Limited has signed a research, development and commercialisation agreement with JDRF, the world's leading type 1 diabetes research charity.

Under the collaboration, Arecor and JDRF will invest equal funds to develop AT271, a liquid combination of insulin and pramlintide, which is used to replace a hormone absent in people with type 1 diabetes.

READ: Arecor progresses with insulin candidate clinical trial

In a statement, the privately-owned biopharmaceutical company said it has been demonstrated that the combined injection of these two drugs at mealtimes helps with controlling the blood sugar level, losing weight and reducing insulin doses.

However, it noted, pramlintide is currently “underutilised” because there is no combined injectable solution containing insulin and patients need to carry out separate injections.

Arecor will use its proprietary formulation technology platform, Arestat to develop a new, co-formulation of pramlintide and insulin.

“The development of a co-formulation of pramlintide-insulin has the promise to significantly improve the quality of life for people living with diabetes by enabling more effective management of this condition,” said Arecor’s chief executive Sarah Howell.

“This collaboration reflects the investment we are making in our proprietary portfolio of diabetes products and we appreciate the support of such a prestigious organisation as JDRF.

The charity has invested £1bn into funding type 1 diabetes research globally since 1970.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Arecor completes dosing in its Phase I clinical trial and...

Arecor's Sarah Howell tells Proactive London's Andrew Scott they've now completed dosing and patient visits in the Austria-based phase I study of its ultra-rapid acting insulin candidate, AT247, with results expected by the end of the year. They've also signed a research, development and...

2 weeks ago

2 min read